HIV MDR is still a relevant issue despite its dramatic drop over the years
- PMID: 31976521
- DOI: 10.1093/jac/dkz554
HIV MDR is still a relevant issue despite its dramatic drop over the years
Abstract
Objectives: To evaluate the prevalence and therapeutic relevance of drug resistance among isolates from ART-experienced HIV-1-infected patients over the past two decades in Italy.
Methods: Dynamics of resistance to one, two and three or more antiretroviral classes were evaluated from 1999-2018. Virological success (VS) after the latest therapy switch was evaluated according to cumulative class resistance and cumulative genotypic susceptibility score (Stanford HIV_DB algorithm).
Results: Among 13 663 isolates (from 6739 patients), resistance to at least one drug class decreased sharply from 1999 to 2010 (≤2001, 84.6%; 2010, 43.6%; P < 0.001), then remained relatively constant at ∼40% during 2010-18, with the proportion of resistance to three or more classes also stable (∼5%). After 2008, integrase inhibitor resistance slightly increased from 5.6% to 9.7% in 2018 and contributed to resistance, particularly in isolates with resistance to three or more classes (one class, 8.4%; two classes, 15.3%; three or more classes, 34.7%, P < 0.001). Among 1827 failing patients with an available follow-up, by 1 year after genotype-guided therapy start the probability of VS was 87.6%. Patients with cumulative resistance to three or more classes and receiving a poorly active regimen showed the lowest probability (62.6%) of VS (P < 0.001) compared with all other patients (≥81.8%). By Cox regression analysis, cumulative MDR and receiving poorly active antiretroviral regimens were associated with a lower hazard of VS compared with those without resistance.
Conclusions: A dramatic drop of HIV-1 drug resistance at failure has been achieved over the last two decades in Italy; resistance to three or more classes is low but present among currently failing patients. Its management still requires a rational and careful diagnostic and therapeutic approach.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database.Int J Antimicrob Agents. 2021 Feb;57(2):106252. doi: 10.1016/j.ijantimicag.2020.106252. Epub 2020 Nov 28. Int J Antimicrob Agents. 2021. PMID: 33259914
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.Curr HIV Res. 2011 Dec 1;9(8):625-9. doi: 10.2174/157016211798998790. Curr HIV Res. 2011. PMID: 22211659
-
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.PLoS One. 2017 Jun 5;12(6):e0178942. doi: 10.1371/journal.pone.0178942. eCollection 2017. PLoS One. 2017. PMID: 28582463 Free PMC article.
-
Management of HIV infection after triple class failure.New Microbiol. 2013 Jan;36(1):23-39. Epub 2013 Jan 1. New Microbiol. 2013. PMID: 23435813 Review.
Cited by
-
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study.Front Immunol. 2024 May 28;15:1394644. doi: 10.3389/fimmu.2024.1394644. eCollection 2024. Front Immunol. 2024. PMID: 38863717 Free PMC article. Clinical Trial.
-
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.BMJ Open. 2024 Feb 10;14(2):e080606. doi: 10.1136/bmjopen-2023-080606. BMJ Open. 2024. PMID: 38341206 Free PMC article.
-
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1.Infect Dis Ther. 2023 Sep;12(9):2321-2335. doi: 10.1007/s40121-023-00870-6. Epub 2023 Sep 26. Infect Dis Ther. 2023. PMID: 37751019 Free PMC article.
-
GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants.Sci Adv. 2023 Jul 14;9(28):eadg2955. doi: 10.1126/sciadv.adg2955. Epub 2023 Jul 12. Sci Adv. 2023. PMID: 37436982 Free PMC article.
-
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0175121. doi: 10.1128/aac.01751-21. Epub 2022 May 3. Antimicrob Agents Chemother. 2022. PMID: 35502922 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous